Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Takeda Pharma (TKPYY)

Takeda Pharma (TKPYY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 25,919,552
  • Shares Outstanding, K 1,562,360
  • Annual Sales, $ 15,935 M
  • Annual Income, $ 1,682 M
  • 60-Month Beta 0.42
  • Price/Sales 1.64
  • Price/Cash Flow 7.52
  • Price/Book 1.36
Trade TKPYY with:
  • Price/Earnings ttm 12.22
  • Earnings Per Share ttm 1.37
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/07/19
  • Annual Dividend & Yield 0.58 (3.48%)
  • Most Recent Dividend 0.288 on 09/27/18
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.5000 +7.03%
on 12/18/18
19.2300 -13.73%
on 11/26/18
-2.6300 (-13.68%)
since 11/21/18
3-Month
15.5000 +7.03%
on 12/18/18
21.9399 -24.38%
on 09/26/18
-4.3650 (-20.83%)
since 09/21/18
52-Week
15.5000 +7.03%
on 12/18/18
31.2900 -46.98%
on 02/01/18
-11.8100 (-41.58%)
since 12/21/17

Most Recent Stories

More News
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX(R) (cabozantinib) in Combination with OPDIVO(R) (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

Exelixis, Inc. (Nasdaq: EXEL) today announced Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX(R) (cabozantinib) in...

TKPYY : 16.5900 (-0.90%)
EXEL : 20.72 (+0.88%)
BioLife Plasma Services Opens First All-Electric Plasma Donation Center

BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the opening of an all-electric plasma donation center in Tukwila, WA. The new...

TKPYY : 16.5900 (-0.90%)
TAK : 17.15 (-0.29%)
Opioid Induced Constipation (OIC) Drugs Market Research Report with Size, Share, Value, CAGR, Outlook, Analysis, Latest Updates, Data, and News 2020-2026

Report Published by Introspective Market Research on Opioid Induced Constipation (OIC) Drugs Market provides detailed description about the collaborations, deals, designations, patent information etc....

AGN : 193.02 (+0.02%)
DSNKY : 25.5100 (-0.12%)
IRWD : 12.35 (+2.24%)
NKTR : 16.51 (+1.54%)
OPHLF : 22.5000 (unch)
PGNX : 4.10 (-9.39%)
TKPYY : 16.5900 (-0.90%)
TBPH : 7.11 (+3.64%)
VRX.TO : 30.80 (-3.33%)
Miravo Healthcare™ Announces Second Quarter 2021 Results

COMTEX_391248163/2669/2021-08-09T07:30:30

ALARF : 9.1497 (-2.49%)
NRIFF : 0.7475 (+0.39%)
TKPYY : 16.5900 (-0.90%)
MRV.TO : 1.36 (-2.86%)
MRVFF : 1.0500 (-2.78%)
Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO(R) (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks

--a^' TAKHZYRO use demonstrated a safety profile consistent with the original pivotal study with prolonged attack-free periods

TKPYY : 16.5900 (-0.90%)
TAK : 17.15 (-0.29%)
Denture Adhesive Market Detailed Analysis, Growth Factors, Top Key Companies, Trends and Developments, 2018-2027

India, Maharashtra, Pune

ABT : 126.79 (-0.51%)
ABBV : 107.73 (-0.32%)
NVS : 83.48 (-1.07%)
PFE : 43.89 (-1.30%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Vingroup collaborates with Arcturus Therapeutics to establish a manufacturing facility in Vietnam for Arcturus’ mRNA Covid-19 vaccine

--News Direct--

TKPYY : 16.5900 (-0.90%)
ARCT : 54.45 (+1.25%)
Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie

--a^' First Quarter FY2021 Reported IRFS-based Financial Results Will Be Updated to Reflect the Impact of the Decision with No Impact on Core and Underlying Financial Results

ABBV : 107.73 (-0.32%)
TKPYY : 16.5900 (-0.90%)
TAK : 17.15 (-0.29%)
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) ("Takeda") today announced financial results for the first quarter of fiscal year 2021 (period ended June 30, 2021). Based on the solid first-quarter...

TKPYY : 16.5900 (-0.90%)
TAK : 17.15 (-0.29%)
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company...

TKPYY : 16.5900 (-0.90%)
TAK : 17.15 (-0.29%)

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 17.1900
1st Resistance Point 16.8900
Last Price 16.5900
1st Support Level 16.3200
2nd Support Level 16.0500
3rd Support Level N/A

See More

52-Week High 31.2900
Fibonacci 61.8% 25.2582
Fibonacci 50% 23.3950
Fibonacci 38.2% 21.5318
Last Price 16.5900
52-Week Low 15.5000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar